Growth Factor–dependent Inhibition of Normal Hematopoiesis by N-ras Antisense Oligodeoxynucleotides

By Tomasz Skorski,* Cezary Szczylisk, Mariusz Z. Ratajczak,§ Lucia Malaguarnera,* Alan M. Gewirtz,$ and Bruno Calabretta±

From the *Jefferson Cancer Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107; †Istituto Regina Elena, 00165 Roma, Italy; and the $Departments of Pathology and Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19103

Summary

To determine whether N-ras expression is required at specific stages of the process of in vitro normal human hematopoiesis, adherent- and T lymphocyte-depleted mononuclear marrow cells (AT-MNC) or highly purified progenitors (CD34+ cells) were cultured in semisolid medium, under conditions that favor the growth of specific progenitor cell types, after exposure to N-ras sense and antisense oligodeoxynucleotides. N-ras antisense, but not sense, oligodeoxynucleotide treatment of AT-MNC and CD34+ cells resulted in a significantly decreased number of granulocyte/macrophage colony-forming units (CFU-GM) induced by interleukin 3 (IL-3) or granulocyte/macrophage colony-stimulating factor (GM-CSF) and of macrophage colonies (CFU-M) induced by M-CSF, but not of granulocytic colonies induced with G-CSF or IL-5. However, the same treatment significantly inhibited colony formation induced by each of the above factors in combination with IL-3. Megakaryocytic colony (CFU-Meg) formation from AT-MNC or CD34+ cells in the presence of IL-6 + IL-3 + erythropoietin (Epo) was also markedly decreased after antisense oligodeoxynucleotide treatment. Erythroid colonies derived from AT-MNC in the presence of Epo (CFU-E) were not inhibited upon antisense treatment, whereas those arising from AT-MNC or CD34+ cells in the presence of IL-3 + Epo (BFU-E) were markedly affected. These results are consistent with the hypothesis that distinct signal transduction pathways, involving N-ras or not, are activated by different growth factors in different hematopoietic progenitor cells.

During the process of hematopoiesis, pluripotent hematopoietic stem cells generate lineage-specific progenitors that proliferate extensively and acquire a distinct phenotype before terminal differentiation into circulating myeloid and erythroid cells (1). This process is regulated by the coordinate activity of several hematopoietic growth factors, which, upon interaction with their membrane receptors, are likely to transmit the proliferation and/or differentiation activating signals from the cell surface membrane to the nucleus by activation of numerous signal-transduction pathways (2–5). Because some hematopoietic growth factors receptors have tyrosine kinase activity, or are associated with other tyrosine kinases (6–8), it seems likely that phosphorylation of tyrosine residues on target molecules is involved in this process. Oncogene products with constitutively enhanced tyrosine kinase activity activate the p21 ras protein (9), a member of a family of GTP-binding proteins that appear to be involved in transduction of growth signals inside the cell (10), via increased amount of the active GTP-bound protein.

The receptors for platelet-derived growth factor and epidermal growth factor transduce signals to initiate DNA synthesis through activation of p21 ras (11, 12). Stimulation of T lymphocyte proliferation by PHA, and their activation via CD3 complex or CD2 antigen, causes activation of p21 ras (13, 14). Increased levels of activated p21 ras, observed after treatment of several cell lines with IL-2, IL-3, and GM-CSF (15), suggest a role for p21 ras in the response of different cell types to growth factor stimulation. To determine whether N-ras is directly involved in the regulation of normal hematopoiesis, we studied the effects of inhibiting N-ras expression on normal hematopoietic proliferation. Our approach is based on the assumption that the generation of hematopoietic colonies in vitro closely reflects the process occurring in vivo under the influence of a variety of hematopoietic growth factors (5) and on the demonstration that antisense oligodeoxynucleotides can inhibit specific gene function in hematopoietic cells (16–18). Our findings support the possibility that N-ras protoon-
cogene is involved in the regulation of human hematopoiesis through a differential growth factor-dependent activation in distinct progenitor cell subpopulations.

Materials and Methods

Cells. Marrows were obtained by aspiration from the iliac crest of healthy volunteers after informed consent. Light-density mononuclear cells, separated on Histopaque-1077 (Sigma Chemical Co., St. Louis, MO) density gradient, were enriched for hematopoietic progenitors after removing adherent cells and T lymphocytes (AT-MNC)\(^1\) as described (19). AT-MNC were used as such or were further enriched for immature hematopoietic progenitor (CD34\(^+\)) cells using HPCA-1 mAb (Becton Dickinson & Co., San Jose, CA) and Dynabead M-450 magnetic polystyrene beads coated with sheep anti-mouse IgG1 (Fc) (Dynal, Oslo, Norway) (20). The yield of CD34\(^+\) cells from AT-MNC ranged between 0.3 and 2.7% of the starting MNC population.

Oligodeoxynucleotides. These were synthesized on a DNA synthesizer (model 380B; Applied Biosystems, Inc., Foster City, CA) by means of \(\beta\)-cyanethyl-phosphoramidite chemistry as described (18). The sequences of \(N\)-ras antisense and sense oligodeoxynucleotides were

5'-CTG TAC TTA TTT TAC TAG GTG GC 3' and 3'-GTT AGT CTA AGT CAT GTG TT 5'

respectively, which is complementary (or corresponding) to 18 nucleotides of exon 1 beginning with the initiation codon. \(N\)-ras mRNA was detected by amplification of a segment of \(N\)-ras exon 1 using the reverse transcription polymerase chain reaction (RT-PCR) technique with a 5' synthetic primer (5' ATC TCA TTT TAC TAG GTG GC 3') and a 3' synthetic primer (5' CTG TGT TCA CTG AGC TCA GT 3').

The amplification product was detected by hybridization to a synthetic oligomer included in the amplified segment (5' GTG GTG GTT GGA GCA GGT GTT GGG AAA AGC GCA CTC 3') encompassing nucleotides 746-784 of the human \(N\)-ras cDNA (21). \(\beta\_\_\_\_m\) microglobulin (\(\beta\_m\)) mRNA levels were also analyzed by RT-PCR. The 5' primer corresponds to nucleotides 280-301 of the \(\beta\_m\) mRNA sequence; the 3' primer corresponds to nucleotides 510-531; a 50-base probe used to detect the amplification product corresponds to nucleotides 351-400 (22).

Oligomer Treatment of the Cells. 10\(^{4}\) AT-MNC or 10\(^{4}\) CD34\(^+\) cells were seeded into 12 \(\times\) 75-mm tubes (Falcon Labware, Oxnard, CA) in 0.4 ml of IMDM supplemented with 2% heat-inactivated human AB serum, recombinant human growth factors, Heps buffer (Hazelton Biologics Inc.) and \(N\)-ras antisense or sense oligodeoxynucleotides. Recombinant human growth factors (Genetics Institute, Cambridge, MA) were IL-6 (125 U/ml), IL-3 (50 U/ml), GM-CSF (12.5 ng/ml), M-CSF (50 U/ml), IL-5 (1:1,000 crude conditioned medium from a CHO cell line constitutively expressing a human IL-5 cDNA), G-CSF (1:10,000 crude conditioned medium from a CHO cell line constitutively expressing a human G-CSF cDNA), and erythropoietin (Epo) (7.5 U/ml). Sense and antisense oligodeoxynucleotides were used at a concentration of 80 \(\mu\)g/ml during the first 18 h of incubation. Then a second dose (40 \(\mu\)g/ml) was added and cells were further incubated for 6 h and plated without washing. Control groups were left untreated.

Colony Assays. Duplicate cultures were prepared in semisolid methylcellulose medium HCC 4230 (Terry Fox Labs, Vancouver, Canada) or plasma clot (18). Concentrations of growth factors and human AB serum during culture were fivefold lower than those used during the oligodeoxynucleotide treatment. For myeloid colony stimulation (CFU-GM, CFU-M, CFU-Eo, or CFU-G), IL-3, GM-CSF, M-CSF, IL-5, and G-CSF were used, alone or in combination. CFU-E were obtained in the presence of Epo alone. BFU-E were induced in the presence of IL-3 and Epo. CFU-Meg were grown in the presence of IL-6, IL-3, and Epo. Cultures were carried out for 10-12 d, except for CFU-E, cultured for 7-9 d. Plates were then scanned with an inverted microscope and the number of colonies (\(\geq 50\) cells) and clusters (8-40 cells) were counted. Myeloid colonies were identified by visual inspection and erythroid colonies were counted after benzidine staining. Immunofluorescence analysis (23) with a glycoprotein IIb/IIIa-specific mAb (24) identified CFU-megakaryocytic (Meg). Different oligodeoxynucleotide preparations, several bone marrow donors, and the same batches of human AB serum and HCC 4230 medium were used. Results of each experiment represent mean ± SD from 8-24 separate colony assays. Student's \(t\) test was used for statistical analysis.

Reverse Transcription Polymerase Chain Reaction (RT-PCR). To analyze the effects of the \(N\)-ras oligodeoxynucleotides exposure on \(N\)-ras mRNA levels, 10\(^{4}\) CD34\(^+\) cells were plated into 96-well plates in 0.1 ml of IMDM supplemented with 2% human AB serum, IL-3 and GM-CSF, Heps buffer, and 80 \(\mu\)g/ml of \(N\)-ras antisense or sense oligodeoxynucleotides. After 12 h, a second dose of oligomer (40 \(\mu\)g/ml) was added and the incubation continued for additional 12 h. Control cells were untreated. Cells were collected separately from each experimental group, centrifuged, washed, and total RNA was extracted as described (20). RNA from each group was divided into two portions. One sample was reverse transcribed using 400 U of Moloney murine leukemia virus reverse transcriptase (Bethesda Research Laboratories, Gaithersburg, MD) and 0.1 \(\mu\)g of 3'-end primer of \(N\)-ras exon 1 for 1 h at 37°C. The second sample was reverse transcribed using the \(\beta\_m\) 3' primer. For single colony RT-PCR analysis, individual colonies were plucked from methylcellulose and resuspended in 50 \(\mu\)l of IMDM; cells were then centrifuged and lysed for 5 min at 4°C in 7 \(\mu\)l of 10 mM Tris-HCl, pH 8.0, 10 mM NaCl, 3 mM MgCl\(_2\) and 2% NP-40. The samples were then centrifuged at 12,000 rpm for 2 min at 4°C and the supernatants were used as a source of mRNA for reverse transcription reaction as above. Resulting cDNA fragments were amplified with 5 U of Taq polymerase (Perkin Elmer Cetus, Norwalk, CT) in the presence of the 5' primer of either \(N\)-ras exon 1 or \(\beta\_m\), generating a 115-bp fragment of \(N\)-ras and a 252-bp fragment of \(\beta\_m\) cDNA during 50 cycles of PCR (25). Reaction products were subjected to electrophoresis in a 2% agarose gel, transferred to \(\alpha\)-Zeta blotting membranes (Bio-Rad Laboratories, Richmond, CA), and hybridized overnight at 55°C using \(N\)-ras or \(\beta\_m\) synthetic oligomer end-labeled with \(\gamma\)-[\(\alpha\]P]ATP and polymerase kinase as described (26). Filters were washed twice with 2x SSC containing 0.1% SDS at 49°C for 30 min and exposed to \(x\)-ray films with intensifying screens. Densitometric measurements of the hybridization bands were performed using an Ultra Scan XL (Pharmacia, LKB) apparatus.

Results

Effect of \(N\)-ras Antisense Oligodeoxynucleotides on Granulocyte/Macrophage Colony Formation. AT-MNC were exposed to oligodeoxynucleotides (80 \(\mu\)g/ml at time 0; 40 \(\mu\)g/ml 18 h later) and plated (5 \(\times\) 10\(^4\) cells/plate) under optimal culture conditions for the growth of specific progenitor cell subsets.

---

\(^{1}\) Abbreviations used in this paper: AT-MNC, adherent- and T lymphocyte-depleted mononuclear narrow cells; \(\beta\_m\), \(\beta\_m\)-microglobulin; Epo, erythropoietin; Meg, megakaryocytic; RT, reverse transcription.
Treatment with sense oligodeoxynucleotide inhibited colony growth stimulated with IL-3, GM-CSF, M-CSF, G-CSF, or IL-5 by 3.9, 1.5, 15.2, 0.4, and 2%, respectively, compared with untreated controls. Instead, treatment with the N-ras antisense oligodeoxynucleotide resulted in 48.7, 36.0, and 67.5% inhibition of colony formation in the presence of IL-3, GM-CSF, or M-CSF, respectively, but did not affect colony formation in the presence of G-CSF or IL-5, compared with sense-treated groups (Table 1). Colony size was only marginally affected by treatment with sense oligodeoxynucleotide, whereas the antisense treatment reduced the size of most colonies growing in the presence of IL-3, GM-CSF, or M-CSF, but not of those growing with IL-5 or G-CSF (data not shown). When AT-MNC were cultured in the presence of IL-3 + GM-CSF, IL-3 + M-CSF, IL-3 + G-CSF, or IL-3 + IL-5, sense oligodeoxynucleotide did not inhibit colony formation significantly (16.9, 7.4, 0, and 12.1% inhibition, respectively) compared with controls, but treatment with N-ras antisense oligodeoxynucleotides resulted in 38.6, 44.8, 35.9, and 38.4% inhibition of colony formation compared with sense-treated cultures (Table 1).

To analyze the effect of N-ras antisense oligodeoxynucleotides on the growth of a more homogeneous, less mature population of hematopoietic progenitors, colony assays were performed using CD34+ cells isolated from AT-MNC (Table 2). Treatment of the cells with sense oligodeoxynucleotides inhibited colony growth stimulated with IL-3, GM-CSF, M-CSF, or G-CSF by only 0.6, 21.7, 16.7, and 10.7%, respectively, compared with controls, and colony size was not affected. Antisense oligodeoxynucleotide treatment, instead, efficiently inhibited the number of colonies induced with IL-3 (73.6%), GM-CSF (53.3%), and M-CSF (61.5%), as compared with values obtained with sense oligomers (Table 2).

As in the case of AT-MNC, residual colony formation stimulated by G-CSF was not affected. IL-5 alone was not studied because CD34+ cells do not form colonies in the presence of this cytokine (27). When IL-3 was combined with GM-CSF, M-CSF, G-CSF, or IL-5, sense oligodeoxynucleotide treatment reduced colony number only slightly (by 10.3, 12.3, 13.3, and 1%, respectively) as compared with controls, whereas antisense treatment significantly inhibited both the size (not shown) and the number of colonies (54.7, 79.1, 59.8, and 37.1%, respectively) as compared with values obtained with the sense oligomer (Table 2).

Effect of N-ras Antisense Oligodeoxynucleotides on Erythroid Colony Formation. The influence of N-ras antisense oligodeoxynucleotides on BFU-E colony formation by AT-MNC and CD34+ cells was evaluated in the presence of IL-3 + Epo (Tables 1 and 2). Sense oligodeoxynucleotide treatment did not significantly diminish colony number (10.3 and 11.2% inhibition, respectively) compared with controls. The antisense oligodeoxynucleotide inhibited colony number by 20.4% (AT-MNC) and 40.3% (CD34+) compared with the sense oligomer, but only slightly reduced BFU-E colony size (not shown). Neither sense nor antisense oligodeoxynucleotides influenced the number or size of CFU-E colonies from AT-MNC in the presence of Epo only (Table 1). Colony growth with Epo only was not studied with CD34+ cells because CFU-E are not contained within this cell population (27).

Effect of N-ras Antisense Oligodeoxynucleotides on Megakaryocytic Colony Formation. AT-MNC and CD34+ cells were incubated in the presence of IL-6 + IL-3 + Epo, and CFU-Meg colonies were identified by mAb immunofluorescence staining. Sense oligodeoxynucleotides did not significantly reduce colony number (8.3 and 14% inhibition com-

Table 1. Effect of N-ras Oligodeoxynucleotides on In Vitro Colony Formation from A-T-MNC

| Inducer               | Control          | Sense            | Antisense         | Percent inhibition~ |
|-----------------------|------------------|------------------|-------------------|---------------------|
| IL-3                  | 337.0 ± 24.1     | 325.7 ± 48.3     | 173.0 ± 39.6      | 48.7 (p = 0.035)    |
| GM-CSF                | 449.0 ± 58.0     | 465.0 ± 1.4      | 287.5 ± 30.4      | 36.0 (p = 0.016)    |
| M-CSF                 | 75.5 ± 9.2       | 64.0 ± 4.2       | 24.5 ± 10.6       | 67.5 (p = 0.039)    |
| G-CSF                 | 119.5 ± 34.6     | 120.5 ± 37.5     | 133.0 ± 25.5      | -10.4 (NS)          |
| IL-5                  | 319.5 ± 46.0     | 312.8 ± 40.8     | 323.3 ± 22.1      | -3.4 (NS)           |
| EPO                   | 304.0 ± 138.7    | 284.9 ± 109.6    | 287.7 ± 135.4     | -0.1 (NS)           |
| IL-3 + GM-CSF         | 431.8 ± 91.5     | 358.6 ± 49.7     | 213.5 ± 55.3      | 38.6 (p <0.001)     |
| IL-3 + M-CSF          | 356.5 ± 43.1     | 330.0 ± 14.1     | 182.0 ± 5.7       | 44.8 (p = 0.005)    |
| IL-3 + G-CSF          | 355.5 ± 17.7     | 355.0 ± 43.1     | 228.0 ± 50.9      | 35.9 (p = 0.014)    |
| IL-3 + IL-5           | 503.5 ± 76.0     | 423.0 ± 36.0     | 260.5 ± 39.6      | 38.4 (p <0.001)     |
| IL-3 + EPO            | 320.6 ± 61.3     | 287.5 ± 41.1     | 228.9 ± 39.6      | 20.4 (p = 0.004)    |
| IL-6 + IL-3 + Epo     | 124.1 ± 22.1     | 113.8 ± 25.6     | 20.8 ± 11.1       | 81.7 (p <0.001)     |

* Values are mean ± SD from duplicate cultures from four to six separate experiments.

† Inhibition of colony formation by antisense oligodeoxynucleotides in comparison with sense-treated groups (in parentheses, statistical significance).
Table 2. Effect of N-ras Oligodeoxynucleotides on In Vitro Colony Formation from CD34+ Cells

| Inducer               | Control       | Sense          | Antisense      | Percent inhibition¹ |
|-----------------------|---------------|----------------|----------------|---------------------|
| IL-3                  | 128.8 ± 27.1  | 128.0 ± 7.6    | 34.0 ± 5.8     | 73.6 (p < 0.001)    |
| GM-CSF                | 116.2 ± 36.7  | 91.0 ± 13.6    | 42.5 ± 2.9     | 53.3 (p < 0.001)    |
| M-CSF                 | 56.2 ± 14.3   | 46.8 ± 9.0     | 18.2 ± 4.3     | 61.5 (p = 0.001)    |
| G-CSF                 | 16.8 ± 5.2    | 15.0 ± 3.6     | 16.0 ± 3.6     | -0.1 (NS)           |
| IL-3 + GM-CSF         | 135.2 ± 17.3  | 121.3 ± 17.6   | 54.9 ± 14.2    | 54.7 (p < 0.001)    |
| IL-3 + M-CSF          | 172.2 ± 14.2  | 151.0 ± 24.8   | 31.5 ± 4.7     | 79.1 (p < 0.001)    |
| IL-3 + G-CSF          | 180.4 ± 18.7  | 156.4 ± 35.9   | 62.8 ± 23.8    | 59.8 (p < 0.001)    |
| IL-3 + IL-5           | 181.0 ± 4.2   | 202.5 ± 28.3   | 127.3 ± 22.8   | 37.1 (p = 0.006)    |
| IL-3 + Epo            | 187.0 ± 50.8  | 166.0 ± 27.6   | 99.1 ± 18.6    | 40.3 (p < 0.001)    |
| IL-6 + IL-3 + Epo     | 21.5 ± 3.5    | 18.5 ± 3.4     | 6.3 ± 2.5      | 66.0 (p < 0.001)    |

* Values are mean ± SD from duplicate cultures from 6-12 separate experiments.
¹ Inhibition of colony formation by antisense oligodeoxynucleotides in comparison with sense-treated groups (in parentheses, statistical significance).

pared with controls), whereas antisense treatment caused strong inhibition of colony formation (81.7 and 66% compared with sense) (Tables 1 and 2). Colony size was only slightly reduced in sense-treated cultures but markedly diminished after antisense treatment (Fig. 1).

Expression of N-ras mRNA in CD34+ Bone Marrow Cells Exposed to N-ras Oligomers. To determine whether the effects of N-ras antisense treatment on colony formation correlated with inhibition of N-ras expression in hematopoietic cells, CD34+ cells were exposed to N-ras sense or antisense oligodeoxynucleotide and levels of N-ras mRNA were analyzed by RT-PCR technique. High levels of N-ras mRNA were detected in untreated (Fig. 2, lane c) as well as in sense-treated CD34+ cells (Fig. 2, lane s). Significantly lower levels of N-ras mRNA were present in cells incubated with antisense oligodeoxynucleotide (Fig. 2, lane as). Densitometric measurement of the N-ras cDNA hybridizing band in sense-versus-antisense-treated samples indicated that the signal from the antisense-treated cells was <5% that from the sense-treated cells. Levels of βm mRNA, used as control, were similar in all samples. Thus, treatment with N-ras antisense oligodeoxynucleotides causes a specific downregulation of N-ras expression in CD34+ cells.

Detection of N-ras Transcripts in Individual Myeloid and Erythroid Colonies. To determine whether the lack of inhibitory effect of N-ras antisense oligodeoxynucleotides on granulocyte and erythroid colony formation was due to the absence of N-ras expression in those specific colonies, single colonies obtained after stimulation with GM-CSF, G-CSF, IL-3 + Epo, or Epo were analyzed for N-ras mRNA expression. Each CFU-E colony consisted of 40-50 cells, whereas the number of cells in the remaining colonies (BFU-E, CFU-GM, and CFU-G) was 200-250. Detection of N-ras mRNA by RT-PCR in each colony type (Fig. 3) indicates that the effect of N-ras antisense oligodeoxynucleotides on the different colonies is not associated with a stage-specific, lineage-dependent pattern of N-ras expression.

Discussion
To assess the functional significance of N-ras expression in normal hematopoietic progenitor cells, we exposed different progenitor cell subsets to N-ras antisense oligodeoxynucleotides and assayed colony formation in the presence of hematopoietic growth factors supporting growth of myeloid, erythroid, or megakaryocytic progenitors. The antisense strategy has been successfully used for the functional analysis of numerous genes (28), including H-ras (29). The antisense oligodeoxynucleotide we used is specific for N-ras, and does not affect H-ras or K-ras expression, because of four and three nucleotide mismatches, respectively; two nucleotide mismatches are sufficient to abrogate the biological effect exerted by an 18-mer fully matched antisense oligodeoxynucleotide (30, 31). Our results provide direct evidence that N-ras is required for growth of normal human hematopoietic cells. The N-ras antisense oligodeoxynucleotide inhibited myeloid colony formation derived from AT-MNC as well as that derived from CD34+ cells in the presence of IL-3, GM-CSF, or M-CSF, but not G-CSF or IL-5, except when combined with IL-3. Colony size of most residual colonies formed after N-ras antisense treatment in the presence of IL-3, or GM-CSF or M-CSF, was reduced compared with the sense-treated and control groups, although colony morphology was not altered.

The number, but not the size, of early erythroid progenitor colonies (BFU-E) growing from AT-MNC or CD34+ cells in presence of IL-3 + Epo was moderately reduced, but no influence of the antisense oligodeoxynucleotide on late
Figure 3. Levels of N-ras mRNA in myeloid and erythroid colonies. Five individual erythroid (CFU-E and BFU-E) and myeloid (CFU-GM and CFU-G) colonies were isolated after 5-d (BFU-E), 7-d (CFU-E and CFU-G), and 10-d (CFU-GM) culture in methylcellulose. Cytoplasmic RNA was extracted and RTPCR performed for detection of N-ras transcripts as described in Materials and Methods. β2m expression served as control, a, BFU-E; b, CFU-GM; c, CFU-G; d, CFU-E colonies.

Figure 3. Levels of N-ras mRNA in myeloid and erythroid colonies. Figure 1. Effect of N-ras oligomers on size of megakaryocytic colony derived from A-T-MNC in the presence of IL6 + IL3 + Epo. (C) control, (S) sense, (AS) antisense.

Figure 2. Expression of N-ras and β2m mRNA in CD34+ cells exposed to N-ras oligodeoxynucleotides. CD34+ cells (10^5/ml) were left untreated (lane c), or exposed to ~80 μg/ml of N-ras sense (lane s) or antisense (lane as) oligodeoxynucleotides, at time 0. After 12 h, a second dose (40 μg/ml) was added. Cells were harvested 12 h later, and mRNA was isolated and divided into two aliquots that were separately amplified with N-ras and β2m-specific primers using RT-PCR. The resulting cDNAs were hybridized to specific 32P end-labeled probes as described in Materials and Methods.

N-ras requirements in normal human hematopoiesis appear to be associated with the activation of specific signal transduction pathways after the interaction of IL3, GM-CSF,
and M-CSF, but not of G-CSF, IL-5, and Epo, with their respective receptors. Our data using GM-CSF and IL-3 support and extend previous observations on in vitro established cell lines. An increase in GTP-bound p21 levels in cells stimulated with PDGF (11), EGF (12), IL-2, IL-3, and GM-CSF, but not IL-4 (15) or IGF-1 (32), has been reported and, based on that observation, it was suggested that p21 ras is required in the signal transduction pathway induced by these growth factors. The human GM-CSF and IL-3 receptors exhibit a striking homology in their primary structure (33); this is likely to explain their crossreactivity with the respective ligands and the apparent use of common molecular mechanisms of signal transduction (34). Accordingly, it might be difficult to determine whether the N-ras requirement is specifically associated with the GM-CSF or IL-3-dependent signal transduction pathway.

We report the first evidence, to our knowledge, that N-ras is involved in the signal transduction pathway activated by M-CSF. Although there is no demonstration that M-CSF induces an increase in GTP-bound p21 levels directly, transformation of NIH 3T3 cells by the oncogenic form of the M-CSF receptor (v-fms) is inhibited by microinjection of the anti-Ras p21 antibody Y13-259 (35), supporting our conclusion that N-ras activation plays an important role also in the proliferative response induced by activation of the nononcogenic form of the M-CSF receptor.

The possibility that the inhibition of BFU-E we observed upon IL-3 + Epo stimulation does not depend directly on an effect of N-ras on erythroid colony formation stimulated by those cytokines cannot be excluded by our data. It has been suggested that PDGF enhances, directly or indirectly, erythroid colony formation induced by Epo (36, 37); the possibility that N-ras activation upon Epo stimulation occurs in response to PDGF, released by accessory cells or present in the serum used for culture, is unlikely because N-ras antisense oligodeoxynucleotide treatment does not affect CFU-E colonies (Table 1).

The receptors for hematopoietic growth factors either have intrinsic tyrosine kinase activity (M-CSF receptor) or are capable to activate these enzymes (IL-3, GM-CSF, G-CSF, and Epo receptors). Although the activation of the N-ras p21 protein after growth factor stimulation might require phosphorylation of the receptors and/or of target molecules, the mechanisms involved are not understood. A mechanism by which p21 ras is maintained in the GTP-bound form involves inactivation of GTPase activating protein (GAP); whether this is affected by phosphorylation or by other mechanisms is not yet clear (13, 15). It is possible, for instance, that the interaction of Epo, or G-CSF or IL-5, with their receptors fails to generate the GTP-bound form of p21 ras or that the signal transduction pathway downstream of Ras is not activated. Based on our observation that growth factor–induced colony formation has differential requirement for N-ras, there appear to be at least two distinct pathways associated with proliferation of hematopoietic progenitor cells: one is associated with IL-3, GM-CSF, and M-CSF stimulation, and the other with G-CSF, IL-5, and Epo activity. Although our findings could be explained on the basis of a lineage-dependent mechanism of N-ras activation, two observations are against this interpretation: (a) residual colonies formed in the presence of GM-CSF after exposure to N-ras oligodeoxynucleotides were morphologically identified as granulocytic, macrophage, and mixed colonies (not shown); and (b) comparable levels of N-ras mRNA were detected in individual erythroid (CFU-E), granulocytic (CFU-G), and granulocyte/macrophage (CFU-GM) colonies (Fig. 3). Further studies are needed to determine the basis for the involvement of N-ras in distinct growth factor–dependent signal transduction pathways.

The physiological role of protooncogenes in hematopoiesis most likely involves the coordinate regulation of proliferation and differentiation. Each step in the process of generating terminally differentiated cells from multipotent and unipotent progenitors is probably under the control of several genes encoding products with distinct functions. We have previously demonstrated that c-myc (18, 20) and c-abl (38) play a regulatory role in normal hematopoiesis, and we now report the involvement of N-ras in the process. Our results underscore the complexity of the regulatory mechanisms involved in hematopoiesis and provide a rational basis to explain the pathological effects that may result from aberrant activation of protooncogenes. It seems not unreasonable to hypothesize that the mutated form of N-ras, which is detected in many cases of acute myelogenous leukemia, bypasses certain regulatory steps associated with the developmental program of normal hematopoietic cells.

We thank Dr. Bice Perussia for critical reading of the manuscript and many useful suggestions, and Dr. K. deRiel for oligomers synthesis.

This work was supported, in part, by National Institutes of Health grants CA-46782 (B. Calabretta) and CA-36896 (A. M. Gewirtz), by American Cancer Society grant CH-492 (B. Calabretta), and by a grant from the Associazione Italiana Ricerca sul Cancro. C. Szczylk is the recipient of a fellowship from the Cancer Research Foundation of America. A. M. Gewirtz is the recipient of a Career Research Development Award. B. Calabretta is a Scholar of the Leukemia Society of America.

T. Skorski is on leave of absence from the Department of Cytophysiology, Medical Center of Postgraduate Education, Warsaw, Poland. C. Szczylk is on leave of absence from the Department of Immunology, Postgraduate Medical Center CSK WAM, Warsaw, Poland.
References

1. Till, J.E., and E.A. McCulloch. 1980. Hemopoietic stem cell differentiation. Biochem. Biophys. Acta. 605:431.
2. Metcalf, D. 1985. The granulocyte-macrophage colony-stimulating factors. Science (Wash. DC). 229:16.
3. Clark, S.C., and R. Kamen. 1987. The human hematopoietic colony-stimulating factors. Science (Wash. DC). 236:1229.
4. Seiff, C.A. 1987. Hematopoietic growth factors. J. Clin. Invest. 79:1549.
5. Nicola, N.A. 1989. Hemopoietic cell growth factors and their receptors. Annu. Rev. Biochem. 58:45.
6. Arait, K., F. Lee, A. Miyajima, S. Miyatake, N. Arai, and T. Yokota. 1990. Cytokines: coordinators of immune and inflammatory responses. Annu. Rev. Biochem. 59:783.
7. Ullrich, A., and J. Schlessinger. 1990. Signal transduction by receptors with tyrosine kinase activity. Cell. 61:203.
8. Cross, M., and T.M. Dexter. 1991. Growth factors in development, transformation, and tumorigensis. Cell. 64:271.
9. Satoh, T., M. Endo, M. Nakafuku, T. Akiyama, T. Yamamoto, and Y. Kaziro. 1990. Accumulation of p21GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity. Proc. Natl. Acad. Sci. USA. 87:7926.
10. Bourne, H.R., D.A. Sanders, and F. McCormick. 1990. The GTPase superfamily: a conserved switch for diverse cell functions. Nature (Lond.). 348:125.
11. Satoh, T., M. Endo, M. Nakafuku, S. Nakamura, and Y. Kaziro. 1990. Platelet-derived growth factor stimulates formation of active p21 GTP complex in Swiss mouse 3T3 cells. Proc. Natl. Acad. Sci. USA. 87:5993.
12. Satoh, T., M. Endo, M. Nakafuku, T. Akiyama, T. Yamamoto, and Y. Kaziro. Accumulation of p21 GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity. Proc. Natl. Acad. Sci. USA. 87:7926.
13. Downward, J., J.D. Graves, P.H. Warne, S. Rayter, and D.A. Cantrell. 1990. Stimulation of p21GTP upon T-cell activation. Nature (Lond.). 346:719.
14. Graves, J.D., J. Downward, S. Rayter, P. Warne, A.L. Tutt, M. Glennie, and D.A. Cantrell. 1991. CD2 antigen mediated activation of the guanine nucleotide binding protein p21GTP in human T lymphocytes. J. Immunol. 146:3709.
15. Satoh, T., M. Nakafuku, A. Miyajima, and Y. Kaziro. 1991. Involvement of ras p21 protein in signal-transduction pathways from interleukin 2, interleukin 3, and granulocyte/macrophage colony-stimulating factor, but not from interleukin 4. Proc. Natl. Acad. Sci. USA. 88:3314.
16. Holt, J.T., R.L. Redner, and A.W. Nienhuis. 1988. An oligomer complementary to c-myc messenger-RNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol. Cell. Biol. 8:963.
17. Wickstrom, E.L., T.A. Bacon, A. Gonzalez, D.L. Freeman, G.H. Lyman, and E. Wickstrom. 1988. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc. Natl. Acad. Sci. USA. 85:1028–1032.
18. Gewirtz, A.M., and B. Calabretta. 1988. A c-myc antisense oligodeoxynucleotide inhibits human hematopoiesis in vitro. Science (Wash. DC). 242:1303.
19. Caracciolo, D., N. Shirsat, G.G. Wong, B. Lange, S. Clark, and G. Rovera. 1987. Recombinant human macrophage colony-stimulating factor (M-CSF) requires subminimal concentration of granulocyte/macrophage (GM-CSF) for optimal stimulation of human macrophage colony formation in vitro. J. Exp. Med. 166:1851.
20. Caracciolo, D., D. Venturelli, M. Valtieri, C. Peschle, A.M. Gewirtz, and B. Calabretta. 1990. Stage-related proliferative activity determines c-myc functional requirements during normal human hematopoiesis. J. Clin. Invest. 85:55.
21. Hall, A., and R. Brown. 1985. Human N-ras: cDNA cloning and gene structure. Nucleic Acids Res. 13:5255.
22. Suggs, S.V., R.B. Wallace, T. Hirose, E.H. Kawashima, and K. Itakura. 1981. Use of synthetic oligonucleotides as hybridization probes: isolation of cloned cDNA sequences for human β2-microglobulin. Proc. Natl. Acad. Sci. USA. 78:6613.
23. Gewirtz, A.M., W.Y. Xu, and K.F. Mangan. 1987. Role of natural killer cells in comparison with T-lymphocytes and monocytes, in the regulation of normal human megakaryocytopoiesis in vitro. J. Immunol. 139:2915.
24. Bennet, J.S., J.A. Hoxie, S.S. Leitman, G. Vilaire, and D.B. Cines. 1983. Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody. Proc. Natl. Acad. Sci. USA. 80:2417.
25. Saiki, R.K., D.H. Gelfand, S. Stoffel, S.J. Scherf, R. Higuchi, G.T. Horn, K.B. Mullis, and H.A. Erlich. 1988. Primer-directed enzymatic amplification of DNA: a thermostable DNA polymerase. Science (Wash. DC). 239:487.
26. Maniatis, T., E.F. Fritsch, and J. Sambrook. 1982. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
27. Brandt, J., N. Baird, L. Lu, E. Strow, and R. Hoffman. 1988. Characterization of a human hematopoietic progenitor cell capable of forming blast cells containing colonies in vitro. J. Clin. Invest. 82:1017.
28. Calabretta, B. 1991. Inhibition of proto-oncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications. Cancer Res. 51:4505.
29. Daska, Y., and E. Wickstrom. 1990. Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T24-transformed NIH3T3 cells. Oncogene Res. 5:267.
30. Anfossi, G., A.M. Gewirtz, and B. Calabretta. 1988. An oligomer complementary to c-myc encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc. Natl. Acad. Sci. USA. 86:3379.
31. Szczyluk, C., T. Skorski, N.C. Nicolaides, L. Manzella, L. Malaguarnera, D. Venturelli, A.M. Gewirtz, and B. Calabretta. 1991. Selective inhibition of leukemia cell proliferation by BCR-
ABL antisense oligodeoxynucleotide. Science (Wash. DC). 253:562.

32. Kaziro, Y., H. Itoh, T. Kozasa, M. Nakafuku, and T. Satoh. 1991. Structure and function of signal-transducing GTP-binding proteins. Annu. Rev. Biochem. 60:349.

33. Kitamura, T., N. Sato, K. Arai, and A. Miyamura. 1981. Expression of cloning of the human IL-3 receptor cDNA reveals a shared β subunit for the human 12-3 and GM-CSF receptors. Cell. 66:1105.

34. Kanakura, Y., B. Druker, S.A. Cannistra, Y. Furukawa, Y. Torimoto, and J.D. Griffin. 1990. Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins. Blood. 76:706.

35. Smith, M.R., S.J. DeGudicibus, and D.W. Stacey. 1986. Requirement for c-ras proteins during viral oncogene transformation. Nature (Lond.). 320:540.

36. Delwiche, F., E. Raines, J. Powell, R. Ross, and J. Adamson. 1985. Platelet-derived growth factor enhances in vitro erythropoiesis via stimulation of mesenchymal cells. J. Clin. Invest. 76:137.

37. Dainiak, N., and S. Kreczko. 1985. Interactions of insulin, Insulin-like growth factor II, and platelet derived growth factor in erythropoietic culture. J. Clin. Invest. 76:1237.

38. Caracciolo, D., M. Valtieri, D. Venturelli, C. Peschle, A.M. Gewirtz, and B. Calabretta. 1989. Lineage-specific requirement of c-abl function in normal hematopoiesis. Science (Wash. DC). 245:1107.